Center for the Study of Hepatitis C, Joan and Sanford I. Weill Medical College of Cornell University, New York, New York 10021, USA.
Clin Gastroenterol Hepatol. 2010 Dec;8(12):1017-29. doi: 10.1016/j.cgh.2010.08.026. Epub 2010 Sep 24.
In addition to its effects in the liver, chronic hepatitis C virus (HCV) infection can have serious consequences for other organ systems. Extrahepatic manifestations include mixed cryoglobulinemia (MC) vasculitis, lymphoproliferative disorders, renal disease, insulin resistance, type 2 diabetes, sicca syndrome, rheumatoid arthritis-like polyarthritis, and autoantibody production; reductions in quality of life involve fatigue, depression, and cognitive impairment. MC vasculitis, certain types of lymphoma, insulin resistance, and cognitive function appear to respond to anti-HCV therapy. However, treatments for HCV and other biopsychosocial factors can reduce quality of life and complicate management. HCV treatment has a high overall cost that increases when extrahepatic manifestations are considered. HCV appears to have a role in the pathogenesis of MC vasculitis, certain types of lymphoma, and insulin resistance. Clinicians who treat patients with HCV infections should be aware of potential extrahepatic manifestations and how these can impact and alter management of their patients.
除了对肝脏的影响外,慢性丙型肝炎病毒(HCV)感染还可能对其他器官系统造成严重后果。肝外表现包括混合性冷球蛋白血症(MC)血管炎、淋巴增生性疾病、肾脏疾病、胰岛素抵抗、2 型糖尿病、干燥综合征、类风湿关节炎样多发性关节炎和自身抗体产生;生活质量下降包括疲劳、抑郁和认知障碍。MC 血管炎、某些类型的淋巴瘤、胰岛素抵抗和认知功能似乎对抗 HCV 治疗有反应。然而,HCV 的治疗和其他生物心理社会因素的治疗会降低生活质量并使管理复杂化。考虑到肝外表现,HCV 的治疗总费用会增加。HCV 似乎在 MC 血管炎、某些类型的淋巴瘤和胰岛素抵抗的发病机制中起作用。治疗 HCV 感染的临床医生应该意识到潜在的肝外表现以及这些表现如何影响和改变他们的患者的管理。